Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Cavallaro

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
European Journal of Neurology|July 15, 2016
Nerve conduction velocity in CMT1A: what else can we tell?F Manganelli, C Pisciotta, M M Reilly, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Is overwork weakness relevant in Charcot-Marie-Tooth disease?G Piscosquito, M M Reilly, A Schenone, et al.
European Journal of Neurology|August 1, 2015
Responsiveness of clinical outcome measures in Charcot-Marie-Tooth diseaseG Piscosquito, M M Reilly, A Schenone, et al.
Journal of Neurology|April 22, 2016
Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaA Cortese, G Vita, M Luigetti, et al.
Journal of Neurology|March 18, 2016
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaA Cortese, G Vita, M Luigetti, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
European Journal of Neurology|July 15, 2016
Nerve conduction velocity in CMT1A: what else can we tell?F Manganelli, C Pisciotta, M M Reilly, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Is overwork weakness relevant in Charcot-Marie-Tooth disease?G Piscosquito, M M Reilly, A Schenone, et al.
European Journal of Neurology|August 1, 2015
Responsiveness of clinical outcome measures in Charcot-Marie-Tooth diseaseG Piscosquito, M M Reilly, A Schenone, et al.
Journal of Neurology|April 22, 2016
Erratum to: Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaA Cortese, G Vita, M Luigetti, et al.
Journal of Neurology|March 18, 2016
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaA Cortese, G Vita, M Luigetti, et al.
Pageof 7